| |
NGS is unlocking new possibilities in discovery and diagnostics, but few solutions can keep up with its needs. Access our toolkit to discover how out-of-the-box NGS empowers innovators to hit the ground running. Learn more. 
|
|
Today's Big NewsJul 14, 2023 |
|
Sciensus offers the infrastructure, regulatory expertise and experience to navigate the complexities of international distribution and get your rare drugs to hard-to-reach patients. Learn more. 
|
|
| By James Waldron Eli Lilly just can't get enough weight loss therapies or acquisitions to bolster its pipeline. The Indianapolis-based company has signed off on a $1.92 billion deal, which covers an upfront payment and potential milestones, for Boston-based Versanis and lead asset bimagrumab. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. |
By Annalee Armstrong Caribou Biosciences CEO Rachel Haurwitz, Ph.D., has nothing but praise for the autologous CAR-T cell therapies that have provided another option for lymphoma patients. It’s just that her CRISPR gene editing company would like to do it better with an off-the-shelf approach. |
Sponsored by Clinical Enrollment Using behavioral data science and social algorithms, this boutique biotech agency creates therapeutic-specific and patient-centric content to bypass traditional channels and speak directly to patients. |
By Nick Paul Taylor Is Roche ready to bet $7 billion to challenge Merck & Co. for a red-hot bowel disease space? That is the assertion of the Wall Street Journal, which reports that the Swiss drug developer is in talks with Roivant Sciences about acquiring the rights to an ex-Pfizer candidate. |
Sponsored by OneStudyTeam Hear why sponsors should equip sites with technology that makes securely capturing pre-screening, recruitment, and enrollment data easier. |
By Helen Floersh A new analysis shows that the NIH spent $8.1 billion on phased clinical trials of drugs approved between 2010 and 2019—about 10% of what the pharma and biotech industry committed over the same period. |
By James Waldron If the sight of two biotechs hopping onto the Nasdaq on the same day isn’t enough of a sign that the freezing IPO waters may be thawing, then the fact both companies have overshot expectations may help warm up sentiment further. |
By Gabrielle Masson Nymox Pharmaceutical has spoken out against two ex-leaders who formed a rebellion based around the company’s refusal to accept a proposed partnership. The biotech said the proposal would have created debt and blamed the two leaders for pushing the deal for their own personal benefit. |
By Nick Paul Taylor A safety signal has derailed Theseus Pharmaceuticals’ quest to develop a gastrointestinal stromal tumor treatment. The dose-limiting toxicity drove the biotech to stop enrollment and end development, sending its stock down 65% and leaving its hopes of navigating the R&D maze resting on other assets. |
By Max Bayer Korro Bio is hitting Wall Street via reverse merger with Frequency Therapeutics, adding $117 million in new financing as well. Frequency has struggled this year after flunking a phase 2 trial of its hearing loss med, spurring reprioritizations and layoffs. |
By Annalee Armstrong CEL-SCI will need to conduct another clinical trial for its Multikine head and neck cancer drug—which the company has long trumpeted as a promising treatment, despite data that says otherwise. |
By Max Bayer,Gabrielle Masson Former BMS R&D czar Rupert Vessey will be the first chief scientist at venture creation firm Flagship Pioneering. Eisai's Ivan Cheung to depart after Leqmebi nabbed full FDA approval. Pfizer CEO Albert Bourla to lead international trade group. |
By Teresa Carey This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
By Conor Hale The agency was previously leery of some of the devices, recommending alternatives after analyses showed possible increases in long-term death risks. |
By Paige Minemyer Healthcare giant UnitedHealth Group kicked off insurer earnings for the second quarter Friday morning, when it reported $5.5 billion in profit alongside double-digit revenue growth. |
By Angus Liu Novartis walked away from BeiGene's TIGIT inhibitor. Takeda pulled the FDA filing for its dengue vaccine after the FDA requested more data. Eisai's Alzheimer's chief Ivan Cheung is handing the baton to group CEO's son. And more. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the state of digital phenotyping, plus the vaccine patent lawsuits, the smallest insulin pump, and the rest of the week's headlines. |
|
|---|
|
|
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
